Loading...
Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer
Lung cancer is difficult to treat with a poor prognosis and a five year survival of 15%. Current molecularly targeted therapies are initially effective in non-small cell lung cancer (NSCLC) patients; however, they are plagued with difficulties including induced resistance and small therapeutically r...
Saved in:
| Published in: | Arch Cancer Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4894332/ https://ncbi.nlm.nih.gov/pubmed/27280107 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|